GSA Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

GSA Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Buy	268,521 +99,970	+59%	+$432K	0.11%	236
2026 Q1	$477K	Buy	+168,551	New	+$571K	0.03%	951
2024 Q1	–	Sell	-48,842	Closed	-$320K	–	1841
2023 Q4	$320K	Buy	+48,842	New	+$316K	0.03%	1083
2023 Q1	–	Sell	-54,976	Closed	-$787K	–	1771
2022 Q4	$787K	Buy	+54,976	New	+$866K	0.1%	335
2022 Q2	–	Sell	-10,114	Closed	-$357K	–	1660
2022 Q1	$357K	Buy	+10,114	New	+$339K	0.05%	768
2021 Q3	–	Sell	-8,095	Closed	-$338K	–	1653
2021 Q2	$338K	Buy	+8,095	New	+$314K	0.04%	867

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

GSA Capital Partners's MRVI Position: Q2 2026 in Review

GSA Capital Partners increased its Maravai LifeSciences (MRVI) stake by 59% in Q2 2026, buying an estimated $432K and bringing the position to 268,521 shares worth $1.68M. The position accounts for 0.11% of the portfolio, ranked #236.

GSA Capital Partners first reported a position in MRVI in Q2 2021 and has held it in 6 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

GSA Capital Partners held 268,521 shares of Maravai LifeSciences worth $1.68M as of Q2 2026.
GSA Capital Partners bought 99,970 Maravai LifeSciences shares in Q2 2026, an estimated $432K.
Maravai LifeSciences made up 0.11% of GSA Capital Partners's portfolio in Q2 2026, its #236 holding.
GSA Capital Partners first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 6 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.